(flu-maz-e-nil) ,


(trade name),


(trade name)


Therapeutic: antidotes
Pregnancy Category: C


Complete/partial reversal of effects of benzodiazepines used as general anesthetics, or during diagnostic or therapeutic procedures.Management of intentional or accidental overdose of benzodiazepines.


Flumazenil is a benzodiazepine derivative that antagonizes the CNS depressant effects of benzodiazepine compounds. It has no effect on CNS depression from other causes, including opioids, alcohol, barbiturates, or general anesthetics.

Therapeutic effects

Reversal of benzodiazepine effects.


Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Protein Binding: 50% primarily to albumin.
Metabolism and Excretion: Metabolism of flumazenil occurs primarily in the liver.
Half-life: Children: 20–75 min; Adults: 41–79 min.

Time/action profile (reversal of benzodiazepine effects)

IV1–2 min6–10 min1–2 hr†
†Depends on dose/concentration of benzodiazepine and dose of flumazenil


Contraindicated in: Hypersensitivity to flumazenil or benzodiazepines;Patients receiving benzodiazepines for life-threatening medical problems, including status epilepticus or ↑ intracranial pressure;Serious cyclic antidepressant overdosage.
Use Cautiously in: Mixed CNS depressant overdose (effects of other agents may emerge when benzodiazepine effect is removed);History of seizures (seizures are more likely to occur in patients who are experiencing sedative/hypnotic withdrawal, who have recently received repeated doses of benzodiazepines, or who have a previous history of seizure activity);Head injury (may ↑ intracranial pressure and risk of seizures);Severe hepatic impairment; Obstetric / Lactation: Safety not established; Pediatric: Children <1 yr (safety not established).

Adverse Reactions/Side Effects

Central nervous system

  • seizures (life-threatening)
  • dizziness (most frequent)
  • agitation
  • confusion
  • drowsiness
  • emotional lability
  • fatigue
  • headache
  • sleep disorders

Ear, Eye, Nose, Throat

  • abnormal hearing
  • abnormal vision
  • blurred vision


  • arrhythmias
  • chest pain
  • hypertension


  • nausea (most frequent)
  • vomiting (most frequent)
  • hiccups


  • flushing
  • sweating


  • pain/injection-site reactions
  • phlebitis


  • paresthesia


  • rigors
  • shivering


Drug-Drug interaction

None significant.


Reversal of Conscious Sedation or General Anesthesia
Intravenous (Adults) 0.2 mg. Additional doses may be given at 1-min intervals until desired results are obtained, up to a total dose of 1 mg. If resedation occurs, regimen may be repeated at 20-min intervals, not to exceed 3 mg/hr.
Intravenous (Children) 0.01 mg/kg (up to 0.2 mg); if the desired level of consciousness is not obtained after waiting an additional 45 sec, further injections of 0.01 mg/kg (up to 0.2 mg) can be administered and repeated at 60-sec intervals when necessary (up to a maximum of 4 additional times) to a maximum total dose of 0.05 mg/kg or 1 mg, whichever is lower. The dose should be individualized based on the patient’s response.
Suspected Benzodiazepine Overdose
Intravenous (Adults) 0.2 mg. Additional 0.3 mg may be given 30 sec later. Further doses of 0.5 mg may be given at 1-min intervals, if necessary, to a total dose of 3 mg. Usual dose required is 1–3 mg. If resedation occurs, additional doses of 0.5 mg/min for 2 min may be given at 20-min intervals (given no more than 1 mg at a time, not to exceed 3 mg per hr).
Intravenous (Children) Unlabeled—0.01 mg/kg (maximum dose 0.2 mg) with repeat doses every minute up to a cumulative dose of 1 mg. As an alternative to repeat doses, continuous infusions of 0.005–0.01 mg/kg/hr have been used.

Availability (generic available)

Injection: 0.1 mg/mL

Nursing implications

Nursing assessment

  • Assess level of consciousness and respiratory status before and during therapy. Observe patient for at least 2 hr after administration for the appearance of resedation. Hypoventilation may occur.
  • Overdose: Attempt to determine time of ingestion and amount and type of benzodiazepine taken. Knowledge of agent ingested allows an estimate of duration of CNS depression.

Potential Nursing Diagnoses

Risk for injury (Indications)
Risk for poisoning (Indications)


  • Do not confuse flumazenil with influenza virus vaccine.
  • Ensure that patient has a patent airway before administration of flumazenil.
    • Observe IV site frequently for redness or irritation. Administer through a free-flowing IV infusion into a large vein to minimize pain at the injection site.
    • Optimal emergence should be undertaken slowly to decrease undesirable effects including confusion, agitation, emotional lability, and perceptual distortion.
    • Institute seizure precautions. Seizures are more likely to occur in patients who are experiencing sedative/hypnotic withdrawal, patients who have recently received repeated doses of benzodiazepines, or those who have a previous history of seizure activity. Seizures may be treated with benzodiazepines, barbiturates, or phenytoin. Larger than normal doses of benzodiazepines may be required.
  • Suspected Benzodiazepine Overdose: If no effects are seen after administration of flumazenil, consider other causes of decreased level of consciousness (alcohol, barbiturates, opioid analgesics).
  • Intravenous Administration
  • pH: 4.0.
  • Diluent: May be administered undiluted or diluted in syringe with D5W, 0.9% NaCl, or LR. Diluted solution should be discarded after 24 hr.Concentration: Up to 0.1 mg/mL.
  • Rate: Administer each dose over 15–30 sec into free-flowing IV in a large vein. Do not exceed 0.2 mg/min in children or 0.5 mg/min in adults.

Patient/Family Teaching

  • Flumazenil does not consistently reverse the amnestic effects of benzodiazepines. Provide patient and family with written instructions for postprocedure care. Inform family that patient may appear alert at the time of discharge but the sedative effects of the benzodiazepine may recur. Instruct patient to avoid driving or other activities requiring alertness for at least 24 hr after discharge.
  • Instruct patient not to take any alcohol or nonprescription drugs for at least 18–24 hr after discharge.
  • Resumption of usual activities should occur only when no residual effects of the benzodiazepine remain.

Evaluation/Desired Outcomes

  • Improved level of consciousness.
    • Decrease in respiratory depression caused by benzodiazepines.
Drug Guide, © 2015 Farlex and Partners


A brand name for FLUMAZENIL.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
Mentioned in ?
References in periodicals archive ?
The antagonist is Flumazenil (Anexate), which can neutralize the effect of benzodiazepine.
Finally, the skin was closed with 4-0 sutures (Ethicon) and the rats received subcutaneously an antidote cocktail consisting of atipamezole (Antisedan, Orion Pharma, 0.75mg/kg), flumazenil (Anexate, Roche, 0.2mg/kg), and naloxone (Naloxon, CuraMed Pharma, Karlsruhe, Germany, 0.12mg/kg).
He cautioned that while it is effective given intravenously at a dose of 0.05-0.1 mg/ kg, it can stop elderly, or overweight people breathing and anexate must be available as an antidote.
Medication stolen includes Adrenaline, Anexate, Midazolam, Diazapan, Glycarlytrinic, Trintate, Chlorphenanie, Septanest, Lignostan and Scamdonest.
Active ingredient Brand names Amphetamine Adderall, Biphetamine, Dexedrine, Dextrostat, Desoxyn Methamphetamine Active ingredient Metabolized to amphetamine Amphetaminil Aponeuron Clobenzorex Aselin, Asenlix, Dinintel, Finedal, Rexigen Ethyl amphetamine Apetinil Fenoproporex Falagan, Lipolin Mefenorex Rondimen, Pondinil, Anexate Prenylamine Segontin, Segentine Active ingredient metabolized to methamphetamine Benzphetamine Didrex Furfenorex Withdrawn due to abuse potential.
Anesthesia was antagonized by subcutaneous injection of atipamezole (Antisedan; Pfizer GmbH), flumazenil (Anexate, Hoffmann-La Roche AG), and naloxone (Narcanti, Janssen Animal Health, Neuss, Germany).
Agents affecting the GABA-A receptor include benzodiazepines, beta-arbolines, and flumazenil (Anexate).